Immuneering Corp (IMRX): Price and Financial Metrics
IMRX Price/Volume Stats
| Current price | $1.43 | 52-week high | $11.92 |
| Prev. close | $1.50 | 52-week low | $1.40 |
| Day low | $1.40 | Volume | 382,300 |
| Day high | $1.54 | Avg. volume | 564,633 |
| 50-day MA | $3.87 | Dividend yield | N/A |
| 200-day MA | $6.60 | Market Cap | 42.40M |
IMRX Stock Price Chart Interactive Chart >
Immuneering Corp (IMRX) Company Bio
Immuneering Corporation provides genetic, genomic, and proteomic data analysis services for pharmaceutical companies to generate biological insights that enhance the clinical and commercial success of medicines. The company was incorporated in 2008 and is based in Cambridge, Massachusetts.
Latest IMRX News From Around the Web
Below are the latest news stories about IMMUNEERING CORP that investors may wish to consider to help them evaluate IMRX as an investment opportunity.
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations- Dosing of first patient in the Phase 1/2a clinical trial expected in early 2024 - CAMBRIDGE, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IMM-6-415, paving the way for the company to initiate a Phase 1/2a clinic |
Here's Why We're Watching Immuneering's (NASDAQ:IMRX) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Immuneering to Present at the 35th Annual Piper Sandler Healthcare ConferenceCAMBRIDGE, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the 35th Annual Piper Sandler Healthcare Conference to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer |
Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates-Dose evaluation portion of IMM-1-104 Phase 1/2a trial approximately two-thirds enrolled; Immuneering’s recommendation for a Phase 2 dose expected in early 2024 - - Expanded clinical development plan for IMM-1-104, Phase 2a portion of study now includes 5 arms (3 monotherapy, 2 combination) and additional sites and investigators - - First IMM-1-104 Phase 2a patient expected to be dosed in early 2024, with initial data from multiple arms expected in 2024 – - IND for IMM-6-415 on track for filing |
Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference– Expanded benchmarking of IMM-1-104 as a single agent across more than 190 patient-aligned models in humanized 3D-tumor growth assays demonstrated high sensitivity in a wide range of MAPK-driven tumor types, including models of RAS and RAF mutant melanoma, pancreatic cancer, and lung cancer – IMM-1-104 in combination with gemcitabine or paclitaxel drove enhanced anti-tumor activity in humanized 3D-tumor growth assays across multiple pancreatic cancer models – Strength of preclinical activity da |
IMRX Price Returns
| 1-mo | -41.15% |
| 3-mo | -76.79% |
| 6-mo | -71.40% |
| 1-year | -86.51% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -80.54% |
| 2023 | 51.55% |
| 2022 | -70.01% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...